Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 1-3 is a gene encoding the variable region of the heavy chain component of immunoglobulins (antibodies), which are key molecules of the adaptive immune system responsible for specific antigen recognition[1][6]. The product of IGHV1-3 forms part of the antigen binding site of immunoglobulin molecules—determining specificity and diversity of antibody responses via combination with corresponding light chain variable regions and through somatic mechanisms like V(D)J recombination and somatic hypermutation[1][7]. IGHV genes—including IGHV1-3—are not independent therapeutic targets or receptors but are structural genetic elements that contribute to the diversity and specificity of antibody-mediated immunity. Mutations or deletions in this and similar IGHV genes can impact immune repertoire and, in rare cases, be associated with immunological or developmental disorders[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 1-3 (IGHV1-3).